|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||33.82 - 34.12|
|52-week range||33.70 - 43.32|
|Beta (5Y monthly)||0.15|
|PE ratio (TTM)||17.96|
|Forward dividend & yield||1.28 (3.76%)|
|Ex-dividend date||16 Mar 2023|
|1y target est||42.98|
Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.
Roche Holding (VTX:ROG) has had a rough three months with its share price down 8.6%. However, stock prices are usually...
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.